Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jeevan Scientific Technology Limited raised Rs. 30.74 crores through a preferential allotment of equity shares on January 2, 2026. The company has now filed its end-of-year monitoring report for the quarter and year ended March 31, 2026, confirming that there are NO deviations or variations in the utilization of these funds. Out of the Rs. 30.74 crores raised, Rs. 10.84 crores has been deployed so far — Rs. 3.66 crores on capital expenditure, Rs. 51.56 lakhs on working capital, Rs. 1.78 crores on working capital and capex for subsidiary, Rs. 3.00 crores on acquisition of API/formulation units, and Rs. 1.89 crores on general corporate purposes. Both the Audit Committee and auditors have confirmed NIL comments after their review, indicating no concerns with the fund utilization.
The absence of any deviation or variation is a positive signal — it means the company is deploying raised funds broadly as intended. Investors can view this as a clean compliance record, though the relatively low deployment ratio (about 35%) may warrant monitoring of spending pace in future quarters.